Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Actavis Reveals Court Injunction On Generic Pulmicort RESPULES Distribution

Actavis Inc. (ACT) Friday confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca (AZN: Quote,AZN.L) to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES (budesonide inhalation suspension) 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the Court.

As a condition of the injunction, the Court has also ordered that AstraZeneca post a bond of $72 million.

Actavis launched its generic product on April 1, 2013, following a ruling from the U.S. District Court for the District of New Jersey that Actavis' 0.25, 0.5 and 1 mg generic version of Pulmicort RESPULES did not infringe United States Patent No. 7,524,834 and that United States Patent No. 6,598,603 was invalid.

On April 2, 2013, the District Court issued a temporary restraining order prohibiting sales of Actavis' generic product to permit AstraZeneca an opportunity to seek injunctive relief with the Federal Circuit.

Pulmicort RESPULES is a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years. For the 12 months ended January 31, 2013, total U.S. brand and generic sales of Pulmicort RESPULES were approximately $1.2 billion.

Register
To receive FREE breaking news email alerts for Actavis Plc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply lower at the open, stocks showed a substantial recovery attempt over the course of the trading day on Monday. The Nasdaq and the S&P 500 bounced well off the one-month intraday lows set in early trading but still closed in the red. While most Americans oppose sending ground troops into combat operations against the terrorist group known as ISIS, the results of a CNN/ORC International poll found that an even larger majority think the American military will still end up putting boots on the ground. With incumbent Sen. Kay Hagan, D-N.C., and Republican challenger Thom Tillis running nearly neck-and-neck in the North Carolina Senate race, the results of a new CNN/ORC International survey suggest that the race could be decided by the number of votes for Libertarian candidate Sean Haugh.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.